VEEV

Veeva Systems (VEEV), a cloud-based software provider for the life sciences industry, has outperformed the broader market with a +12.3% return over the past month. The company shows strong earnings growth of +14.2% year-over-year for the current quarter and consistent revenue growth of +15.1%. However, with a Zacks Rank #3 (Hold) rating and a D valuation grade indicating premium pricing relative to peers, the stock is expected to perform in line with the broader market in the near term.

Veeva Systems expanded its partnership with IQVIA, with IQVIA selecting additional Veeva clinical operations applications as enterprise standards for clinical development studies. The agreement covers CTMS, eTMF, Study Startup, and Site Connect tools, building on their previous EDC partnership. This expansion is expected to strengthen Veeva's presence in clinical research, improve trial efficiency, and create cross-selling opportunities, though financial terms and deployment timelines were not disclosed.

Veeva Systems closed at $301.63, up 1.95% and outperforming the broader market decline. The stock has gained 11.36% over the past month, significantly outpacing the Medical sector's 1.06% gain.

Upcoming earnings are expected to show 14.22% EPS growth and 15.11% revenue growth quarter-over-quarter, with full-year projections of $9.22 EPS and $3.69 billion revenue. The company holds a Zacks Rank of #3 (Hold) with a Forward P/E of 32.09, trading in line with its industry average.